Sign In  |  Register  |  About Sunnyvale  |  Contact Us

Sunnyvale, CA
September 01, 2020 10:10am
7-Day Forecast | Traffic

  • Search Hotels in Sunnyvale

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Galderma

< Previous 1 2 Next >
Galderma’s Phase III OLYMPIA 1 Data Published in JAMA Dermatology Demonstrate That Nemolizumab Improves Core Signs and Symptoms of Prurigo Nodularis
From Galderma
Via Business Wire
Celebrating 25 Years of Sculptra®: New Data and Recent Approval in China Cements Galderma’s Leadership in Regenerative Biostimulation
From Galderma
Via Business Wire
Galderma Brings Together Over 650 Healthcare Professionals from Asia-Pacific to Elevate Knowledge of Future Aesthetic Trends
From Galderma
Via Business Wire
ASDS 2024: New Phase III READY-4 Data Demonstrate Long-Term Safety and Efficacy of Galderma’s RelabotulinumtoxinA (Relfydess™)
From Galderma
Via Business Wire
EADV 2024 Late Breaking News Sessions: New Galderma Data Demonstrating Nemolizumab’s Long-term Efficacy and Safety in Atopic Dermatitis and Durability in Prurigo Nodularis to Be Shared During Three Oral Presentations
From Galderma
Via Business Wire
Galderma Reaffirms Its Leadership in Dermatology With Extensive Presence at EADV 2024
From Galderma
Via Business Wire
Galderma Receives U.S. FDA Approval for Nemluvio® (nemolizumab) for Adult Patients Living With Prurigo Nodularis
From Galderma
Via Business Wire
Galderma to pursue a new scientific partnership with L’Oréal to further advance its category leadership in dermatology
From Galderma
Via Business Wire
Galderma’s Relfydess™ (RelabotulinumtoxinA) Receives Positive Decision for Use in Europe
From Galderma
Via Business Wire
PHASE III ARCADIA 1 and 2 Trial Primary Results Published in The Lancet: Galderma’s Nemolizumab Improves Key Aspects of Atopic Dermatitis – Itch, Skin Lesions and Sleep Disturbance
From Galderma
Via Business Wire
Galderma Introduces High Potency Cetaphil Serums Designed for Sensitive Skin
From Galderma
Via Business Wire
Galderma Granted Key Manufacturing License Updates for New Biologics Capabilities at Its Center of Excellence
From Galderma
Via Business Wire
Galderma Launches Restylane® VOLYME™ in China – One of the World’s Fastest Growing Aesthetics Markets
From Galderma
Via Business Wire
AMWC 2024: Galderma to Share New Data From Its Leading Injectable Aesthetic Portfolio
From Galderma
Via Business Wire
Galderma @ AAD 2024: New Data Demonstrate the Long-Term Efficacy of Nemolizumab in Prurigo Nodularis and Its Durability in Atopic Dermatitis
From Galderma
Via Business Wire
Galderma Announces Record 2023 Net Sales of Over 4 B USD and Significant Core EBITDA Margin Expansion
From Galderma
Via Business Wire
Galderma to Showcase Latest Updates From Its Broad, Innovative and Leading Dermatology Portfolio at the 2024 American Academy of Dermatology Annual Meeting
From Galderma
Via Business Wire
CORRECTING and REPLACING, Galderma Announces Regulatory Filing Acceptance for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in the U.S. and EU
From Galderma
Via Business Wire
Galderma Takes the ‘Face of Cetaphil®’ to the Runway at New York Fashion Week
From Galderma
Via Business Wire
Galderma Launches ‘NEXT’, a Ground-Breaking Trend Report That Unveils the Future of Aesthetics
From Galderma
Via Business Wire
Galderma Celebrates 25 Years of Excellence in Biostimulation With Sculptra® at the 2024 IMCAS
From Galderma
Via Business Wire
IMCAS 2024: Galderma to Present Latest Updates From Its Unparalleled Aesthetics Portfolio Reinforcing Its Leadership Position
From Galderma
Via Business Wire
Galderma Announces Regulatory Approval for Restylane® SHAYPE™, a New Hyaluronic Acid Injectable Designed for Augmenting the Chin Region
From Galderma
Via Business Wire
TOXINS 2024: Galderma’s Phase III RelabotulinumtoxinA Results Demonstrate Positive Efficacy and Long Duration of Effect When Treating Frown Lines and Crow’s Feet Simultaneously
From Galderma
Via Business Wire
Results From Galderma’s Phase IIIb Trials Demonstrate Rapid and Long-Lasting Effect of RelabotulinumtoxinA on Crow’s Feet and Frown Lines
From Galderma
Via Business Wire
Galderma Reports Record Net Sales of Over 3 B USD for the First Nine Months of 2023 With Strong Growth Momentum Across All Product Categories
From Galderma
Via Business Wire
Galderma Unveils Bold Ambition in Neuromodulation at Liquid Live Event
From Galderma
Via Business Wire
Galderma @ EADV 2023: Phase III Trials Demonstrate Nemolizumab’s Efficacy and Rapid Onset of Action in Atopic Dermatitis and Prurigo Nodularis
From Galderma
Via Business Wire
EADV 2023: Galderma to Present New Data Showcasing Its Continued Leadership in Dermatology
From Galderma
Via Business Wire
Galderma announces progress with RelabotulinumtoxinA regulatory submissions
From Galderma
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Sunnyvale.com & California Media Partners, LLC. All rights reserved.